Fig 2: VEGFA and flow pattern govern the S>R transition(A, C, E, and G) Top: scheme of designated compound injection and collection of samples; Bottom: representative image of the vascular network following designated compound treatment.(B, D, F, and H) Top: predicted strength of each morphogen based on designated compound treatment. Bottom: distribution of K- (blue) and F- (red) indexes within 500 µm of the SF. Solid line represents mean, and light area represents SEM. Dashed gray line represents random polarity. Gray rectangle defines each compound-treated S>R transition. Dashed gray bounding rectangle shows control S>R transition (defined in Figure 2D).(I) Box plot for the cellular S>R transition in each retina of control, captopril, angiotensin-II, VEGFA and sFLT1 retinas. n = 11 control; n = 9 captopril; n = 4 angiotensin II; n = 7 VEGFA; n = 4 sFLT1. p values from Mann-Whitney test between control and the corresponding group. Whiskers: min. to max.(J) k-means clustering analysis of vessel morphometrics for designated conditions projected into the binary PCA clustering space defined in Figure 1C. Each dot represents one bin for each retina.(K) Ratio of class 1 bins over total bins for designated conditions. n = 14 control; n = 9 captopril; n = 8 angiotensin II; n = 7 VEGFA; n = 9 sFLT1. p values of a two-tailed Mann-Whitney test between control and the corresponding group. Error bars: SEM.